» Articles » PMID: 38521881

NNT-AS1 in CAFs-derived Exosomes Promotes Progression and Glucose Metabolism Through MiR-889-3p/HIF-1α in Pancreatic Adenocarcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 24
PMID 38521881
Authors
Affiliations
Soon will be listed here.
Abstract

It is metabolic and signaling crosstalk between stromal cells and tumors in the tumor microenvironment, which influences several aspects of tumor formation and drug resistance, including metabolic reprogramming. Despite considerable findings linking lncRNAs in HIF-1-related regulatory networks to cancer cell, little emphasis has been given to the role in communication between cancer-associated fibroblasts (CAFs) and tumor cells. Previously, we observed that NNT-AS1 was substantially expressed in CAFs cells and CAFs exosomes, and subsequently investigated the influence of CAFs exosomal NNT-AS1 on glucose metabolism, proliferation, and metastasis of pancreatic ductal adenocarcinoma (PDAC) cells. Transmission electron microscopy was used to examine exosomes secreted by PDAC patient-derived CAFs. qRT-PCR was used to evaluate the expression of NNT-AS1, miR-889-3p, and HIF-1. The role of CAFs-derived exosomal NNT-AS1 in PDAC cell progression and metabolism have been identified. Dual luciferase reporter assays examined the binding between NNT-AS1, miR-889-3p, and HIF-1. After PDAC cells co-culture exosomes secreted by CAFs, we found that they alter glucose metabolism, proliferation, and metastasis. In PDAC cells, CAF-derived exosomal lncRNA NNT-AS1 acted as a molecular sponge for miR-889-3p. Furthermore, HIF-1 could be targeted by miR-889-3p and was controlled by NNT-AS1. This study explores the mechanism by which NNT-AS1 influences the interaction of CAFs on glycolytic remodeling, proliferation, and metastasis of tumor cells through regulating miR-889-3p/HIF-1α, which also helps discover new clinical treatment targets for PDAC.

Citing Articles

Exosomes: a double-edged sword in cancer immunotherapy.

Chen J, Hu S, Liu J, Jiang H, Wang S, Yang Z MedComm (2020). 2025; 6(3):e70095.

PMID: 39968497 PMC: 11831209. DOI: 10.1002/mco2.70095.


Crosstalk between cancer-associated fibroblasts and non-neuroendocrine tumor cells in small cell lung cancer involves in glycolysis and antigen-presenting features.

Lu Y, Li H, Zhao P, Wang X, Shao W, Liu Y Mol Med. 2024; 30(1):274.

PMID: 39722014 PMC: 11669202. DOI: 10.1186/s10020-024-01051-y.


Long non-coding RNAs are involved in the crosstalk between cancer-associated fibroblasts and tumor cells.

Yang C, Shu J, Li Y, Zhao N, Liu X, Tian X Front Immunol. 2024; 15:1469918.

PMID: 39717771 PMC: 11663902. DOI: 10.3389/fimmu.2024.1469918.


Extracellular Vesicle lncRNAs as Key Biomolecules for Cell-to-Cell Communication and Circulating Cancer Biomarkers.

Papoutsoglou P, Morillon A Noncoding RNA. 2024; 10(6).

PMID: 39585046 PMC: 11587107. DOI: 10.3390/ncrna10060054.


Drug resistance and tumor immune microenvironment: An overview of current understandings (Review).

Liu Y, Liang J, Zhang Y, Guo Q Int J Oncol. 2024; 65(4).

PMID: 39219258 PMC: 11387120. DOI: 10.3892/ijo.2024.5684.

References
1.
Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M . Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018; 103:939-946. DOI: 10.1016/j.biopha.2018.04.087. View

2.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

3.
Cai Y, Dong Z, Wang J . LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci. 2018; 22(15):4879-4887. DOI: 10.26355/eurrev_201808_15624. View

4.
Kobayashi H, Enomoto A, Woods S, Burt A, Takahashi M, Worthley D . Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(5):282-295. DOI: 10.1038/s41575-019-0115-0. View

5.
Li Y, Zhao Z, Liu W, Li X . SNHG3 Functions as miRNA Sponge to Promote Breast Cancer Cells Growth Through the Metabolic Reprogramming. Appl Biochem Biotechnol. 2020; 191(3):1084-1099. PMC: 7320061. DOI: 10.1007/s12010-020-03244-7. View